Further reinforcing the view that Trpv1 inhibitors may be a therapeutic dead-end for treating DS, the selective inhibitor of Trpv1 receptors, SB-705498, failed to ameliorate seizure phenotypes in the F1.Scn1a+/− mice. Here, SCN1A is linked to Dravet syndrome.